PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
18331972-12	2008	These findings suggest that COX-1 is a significant pathway for basal PGE2 production from the basolateral faces of both nonglandular and glandular equine gastric mucosae in vitro.	Dinoprostone	69-73	cytochrome c oxidase subunit I	Equus caballus	28-33
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	Phenylbutazone	45-59	cytochrome c oxidase subunit I	Equus caballus	0-5
17217400-7	2007	Results of in vitro COX selectivity assays showed that etodolac was only slightly selective for COX-2 with a COX-1/COX-2 selectivity ratio effective concentration (EC)50 of 4.32 and for EC80 of 4.77.	Etodolac	55-63	cytochrome c oxidase subunit I	Equus caballus	109-114
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	flunixin	61-69	cytochrome c oxidase subunit I	Equus caballus	0-5
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	carprofen	71-80	cytochrome c oxidase subunit I	Equus caballus	0-5
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	Meloxicam	85-94	cytochrome c oxidase subunit I	Equus caballus	0-5
11202384-3	2000	There are 2 isoforms of cyclooxygenase: COX-1, which constitutively produces prostaglandins and COX-2, which is induced by inflammation.	Prostaglandins	77-91	cytochrome c oxidase subunit I	Equus caballus	40-45
15563928-8	2005	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable COX-1 prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	Phenylbutazone	171-185	cytochrome c oxidase subunit I	Equus caballus	120-125
15563928-8	2005	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable COX-1 prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	Etodolac	207-215	cytochrome c oxidase subunit I	Equus caballus	120-125
12358053-3	2002	It was hypothesised that the nonselective COX inhibitor flunixin would retard repair of bile-injured colon by preventing production of reparative prostaglandins, whereas the selective COX-2 inhibitor, etodolac would not inhibit repair as a result of continued COX-1 activity.	flunixin	56-64	cytochrome c oxidase subunit I	Equus caballus	260-265
11202384-4	2000	We hypothesised that the nonspecific cyclooxygenase inhibitor flunixin meglumine would retard repair of ischaemic intestinal injury by preventing production of reparative prostaglandins, whereas the selective COX-2 inhibitor, etodolac, would permit repair as a result of continued COX-1 prostaglandin production.	flunixin meglumine	62-80	cytochrome c oxidase subunit I	Equus caballus	281-286
28103874-8	2017	For ASA, IC50 were 0.50 mug/mL (COX-1) and 5.14 mug/mL (COX-2).	Aspirin	4-7	cytochrome c oxidase subunit I	Equus caballus	32-37
25075617-9	2015	CONCLUSION: In the present study, although the COX-2 selective action of cimicoxib was not apparent, a relatively low concentration of cimicoxib resulted in both COX-1 and -2 inhibition in horses.	cimicoxib	135-144	cytochrome c oxidase subunit I	Equus caballus	162-174
25710756-1	2015	OBJECTIVE: To evaluate ex vivo cyclooxygenase (COX) inhibition and compare in vitro and ex vivo COX-1 inhibition by flunixin meglumine and firocoxib in horses.	flunixin meglumine	116-134	cytochrome c oxidase subunit I	Equus caballus	96-101
25710756-9	2015	RESULTS: At 2 and 24 hours after NSAID administration, COX-1 activity was reduced, compared with baseline activity, for the flunixin meglumine group only and relative COX-1 activity was significantly greater for the firocoxib group, compared with that for the flunixin meglumine group.	firocoxib	216-225	cytochrome c oxidase subunit I	Equus caballus	167-172
25710756-12	2015	CONCLUSIONS AND CLINICAL RELEVANCE: Compared with flunixin meglumine, firocoxib had COX-1-sparing effects ex vivo in equine patients that underwent elective surgery.	firocoxib	70-79	cytochrome c oxidase subunit I	Equus caballus	84-89
25582761-4	2015	An additional objective was to characterize the effects of flunixin on COX-1 and COX-2 inhibition when drug concentrations reached the recommended regulatory threshold.	flunixin	59-67	cytochrome c oxidase subunit I	Equus caballus	71-76
21565533-4	2012	SC-560 acted as a selective COX-1 inhibitor, tepoxalin as a dual inhibitor with potent activity against COX-1, and NS 398 as a preferential COX-2 inhibitor.	SC 560	0-6	cytochrome c oxidase subunit I	Equus caballus	28-33
21281197-3	2011	PROCEDURES: Half the maximal inhibition (EC50) of robenacoxib for COX-1 and COX-2 activity was established in bloods samples from 6 horses via measurement of thromboxane B2 (TXB2) and prostaglandin E2 concentrations, respectively; COX selectivity was subsequently calculated.	robenacoxib	50-61	cytochrome c oxidase subunit I	Equus caballus	66-71
21036634-7	2011	Tepoxalin showed a strong and long-lasting ex vivo inhibitory activity against cyclooxygenase (COX)-1, mainly due to its main metabolite RWJ-20142.	tepoxalin	0-9	cytochrome c oxidase subunit I	Equus caballus	79-101
21281197-8	2011	RESULTS: The mean +- SD EC50 value of robenacoxib for COX-1 and COX-2 was 11.46 +- 4.46 muM and 0.19 +- 0.07 muM, respectively, resulting in a COX selectivity ratio of 61.01.	robenacoxib	38-49	cytochrome c oxidase subunit I	Equus caballus	54-59
21219338-6	2011	Results of in vitro COX selectivity assays showed that deracoxib was selective for COX-2 with a COX-1/COX-2 ratio of 25.67 and 22.06 for the IC(50) and IC(80) , respectively.	deracoxib	55-64	cytochrome c oxidase subunit I	Equus caballus	96-101
18565556-4	2009	SC-560, selective COX-1 inhibitor, was devoid of significant effects on ileal motility.	SC 560	0-6	cytochrome c oxidase subunit I	Equus caballus	18-23